Live
- G20 Leaders Will Talk About Climate, Taxes, and Trump's Return in Brazil
- COP29: CDRI announces $8 million funding for 12 projects to address climate crisis
- Anti-Telgu remarks: Actor Kasthuri Shankar moves court for bail
- Samsung AR Smart Glasses Set to Launch in 2025, Featuring Ray-Ban Meta-Like Design
- Kerala Industries Minister confident that new policy will boost plantation sector
- Madras HC plans inter-departmental monitoring committee to combat drug use in TN
- Bihar: Spotted deer dies due to heart attack in Banka district
- Mushtaq Ali T20: Shami to spearhead Bengal bowling attack, Gharami named captain
- Kharge's clarion call to oust Maharashtra's BJP-backed MahaYuti
- Why Ukraine’s Use of US Missiles Against Russia Could Lead to World War 3
For The First Time In Medical History Cancer Vanishes From Patients During Drug Trial
- A modest clinical trial discovered that every single rectal cancer patient who got an experimental treatment saw their disease vanish.
- 18 patients took a medicine named Dostarlimab for six months in a limited clinical trial done by Memorial Sloan Kettering Cancer Center, and all of them saw their tumours shrink at the end.
A modest clinical trial discovered that every single rectal cancer patient who got an experimental treatment saw their disease vanish. This finding is believed to be a miracle and in the medical history.
According to sources,18 patients took a medicine named Dostarlimab for six months in a limited clinical trial done by Memorial Sloan Kettering Cancer Center, and all of them saw their tumours shrink at the end.
The specialist stated that Dostarlimab is a medicine made in a lab that functions as a surrogate for antibodies in the human body. Experts stated that the malignancy is undetectable by physical examination, endoscopy, positron emission tomography or PET scans, or MRI scans. This shows that Dostarlimab has the potential to be a 'possible' cure for one of the most lethal tumours.
As per reports, individuals in the clinical experiment had previously received treatments such as chemotherapy, radiation, and invasive surgery, all of which could cause bowel, urinary, and sexual dysfunction. The 18 patients expected to have to go through these surgeries as the next step in the research. However, they were surprised to learn that no more therapy was required.
Experts were astounded by the trial's outcomes, stating that total remission in every single patient is "unheard-of," reported The Times Of India. Experts praised the study because not all of the participants experienced serious side effects from the medication trial.
Dr. Alan P. Venook, a colon cancer specialist at the University of California stated that the complete remission in every single patient is "unheard of."
Patients in the trial were given Dostarlimab every three weeks for six months. The doctors added that it's worth noting that they were all in the same stage of cancer. The cancer had progressed locally in the rectum but had not migrated to other organs. They further added that no no patients had received chemoradiotherapy or surgery, and no cases of progression or recurrence had been recorded during follow-up.
